FDA-Cleared

FDA Cleared Patented Facial RPM AI

Smartphone-based Facial remote patient management (RPM) AI provides an affordable alternative to costly monitoring devices. FDA-cleared and patent-protected, it targets conditions like hypertension and CKD. Ready for deployment, it aims to revolutionize personalized medicine, beginning with mental health.

Problem
  • Current RPM devices are expensive, hard to use, <5% adoptions.
  • 1 out of 8 with mental problems in the 8+ billion population globally.
  • In USA, 100M with hypertension, 37 M CKD, 50 M Diabetes, and more.
Solution
  • Contactless Facial RPM AI is easy to use, quick, low-cost, and convenient, and it works with any smartphone.
  • MedGenie for personalized precision AI medicine, starting ith mental health and wellness. FHIR architecture empower long term integration with hospitals, clinics, software, data and device vendors.
Progress
  • Patents: 12 issued, 5 patent-pending for A1c, Hb, etc.
  • FDA: Cleared RPM SDK for HR. RR Q4 2024, O2 Sat in Q4 2025, & BP Q4 2026.
  • 26 M digital-marketing millennials data, ready to deploy in Apple, Android, and Chat GPT stores. GPHT owns major of SofinNetwork.com and gpheart.com.

Want to learn more?

Join our active discord community to connect with researchers, patients, and supporters working together to advance the future of kidney health.

discord icon

Explore more project proposals

KLF15 Agonist Phase I
KLF15 Agonist Phase I

The KLF15 Agonist Phase I project targets albuminuria in chronic kidney disease, offering a potentially safer and more effective alternative to glucocorticoid therapy for conditions like FSGS and MCD. With promising efficacy and reduced toxicity, this novel approach is progressing towards patent licensing and IND roadmap development, aiming for accelerated FDA approval.

View project

CareToken: Unlocking the Potential of Healthcare Assets
CareYield: Unlocking the Potential of Healthcare Assets

CareYield leverages blockchain, AI, and community to tokenize healthcare assets, creating a liquid marketplace. It aims to accelerate innovation, improve outcomes, and reduce costs, targeting crypto investors while maintaining regulatory compliance.

View project

Decentralized Independent Physician Association (DeIPA)
Decentralized Independent Physician Association (DeIPA)

KidneyDAO's DeIPA is a revolutionary model that demonstrates the potential of CareYield's platform. By leveraging blockchain technology, artificial intelligence, and tokenization, DeIPA has addressed the limitations of traditional IPAs, unlocking new opportunities for growth, efficiency, and patient care.

View project

Dialysis AI Humanoid Robotic Staffing
Dialysis AI Humanoid Robotic Staffing

The Dialysis AI Humanoid Robotic Staffing project tackles the nephrology professional shortage through an AI-driven staffing platform, patient-provider matching app, and humanoid robots. With a revenue-generating platform already operational and patent-pending AI and robotic solutions in development, it aims to optimize dialysis care delivery and staffing efficiency.

View project

Intel MedPatch AI
Intel MedPatch AI

Intel MedPatch AI tackles medication non-compliance through automated lab testing and microneedle drug delivery. This system aims to reduce healthcare costs and medication errors, especially for elderly and rural patients. With patents for CKD and CHF, an obesity management grant, and potential Epogen partnership, it's progressing towards wider application.

View project

Are you working on a project to advance kidney health?  
We offer research funding  and translational support for
promising and innovative projects in kidney health.

Learn more about how we can help accelerate your research.

Learn more about the KNEY token

Everything you need to know about the governance token that powers our community.